Wei Yu
Impact in
- Cancer Research top 5%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- Pancreatic and Hepatic Oncology Research
- Cancer Cells and Metastasis
- Lung Cancer Research Studies
Papers in
-
- Epigenetics and DNA Methylation 17
- Hedgehog Signaling Pathway Studies 7
- RNA modifications and cancer 6
- Oncology 31
- Cancer Immunotherapy and Biomarkers 13
- Co-authors
- Sharmila Shankar (13 shared papers)Rohit Srivastava (12 shared papers)Yiming Ma (9 shared papers)Anju Shrivastava (4 shared papers)Raj Kumar Verma (3 shared papers)Jing Yang (3 shared papers)John R. Falck (3 shared papers)Achim Rittmeyer (8 shared papers)
- Journals
- Journal of Clinical Oncology (8 papers)Journal of Cellular and Molecular Medicine (5 papers)Scientific Reports (4 papers)Journal of Thoracic Oncology (4 papers)Frontiers in Pharmacology (4 papers)
- Partner nations
- ChinaUnited StatesGermany
In The Last Decade
Wei Yu
126 papers receiving 2.7k citations
Wei Yu's Hit Papers
Peers
Comparison fields: 5 of 138
- Cancer Research 506
- Oncology 901
- Pharmacology 192
- Molecular Biology 1.2k
- Pulmonary and Respiratory Medicine 464
Countries citing papers authored by Wei Yu
This map shows the geographic impact of Wei Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wei Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wei Yu more than expected).
Fields of papers citing papers by Wei Yu
This network shows the impact of papers produced by Wei Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wei Yu. The network helps show where Wei Yu may publish in the future.
Co-authors
The 25 scholars most cited alongside Wei Yu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 131 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2008 | 146 | |
| 2 | 2020 | 112 | |
| 3 | 2018 | 105 | |
| 4 | Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer Hit paper breakdown → | 2023 | 102 |
| 5 | 2018 | 86 | |
| 6 | 2013 | 79 | |
| 7 | 2010 | 78 | |
| 8 | 2012 | 72 | |
| 9 | 2016 | 66 | |
| 10 | 2014 | 64 | |
| 11 | 2016 | 63 | |
| 12 | 2020 | 62 | |
| 13 | 2017 | 61 | |
| 14 | 2015 | 59 | |
| 15 | 2020 | 56 | |
| 16 | 2018 | 54 | |
| 17 | 2003 | 53 | |
| 18 | 2018 | 50 | |
| 19 | 2019 | 47 | |
| 20 | 2021 | 43 |
About Wei Yu
Wei Yu is a scholar working on Molecular Biology, Oncology, Pulmonary and Respiratory Medicine, Cancer Research and Surgery, having authored 131 papers that have together received 2.7k indexed citations. Recurring topics across this work include Epigenetics and DNA Methylation (17 papers), Cancer Immunotherapy and Biomarkers (13 papers), Lung Cancer Treatments and Mutations (12 papers), Pharmacological Effects of Natural Compounds (11 papers), Cancer-related molecular mechanisms research (9 papers), Hedgehog Signaling Pathway Studies (7 papers), Ferroptosis and cancer prognosis (7 papers) and RNA modifications and cancer (6 papers). The work is most often cited by research in Cancer Research (506 citations), Oncology (901 citations), Pharmacology (192 citations), Molecular Biology (1.2k citations) and Pulmonary and Respiratory Medicine (464 citations). Wei Yu has collaborated with scholars based in China, United States and Germany. Frequent co-authors include Sharmila Shankar, Rohit Srivastava, Yiming Ma, Anju Shrivastava, Raj Kumar Verma, Jing Yang, John R. Falck, Achim Rittmeyer, Jing Yan and Marcus Ballinger. Their work appears in journals such as Journal of Clinical Oncology, Journal of Cellular and Molecular Medicine, Scientific Reports, Journal of Thoracic Oncology and Frontiers in Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.